Enhancing Therapeutic Cellular Prostate Cancer Vaccines
Abstract
Prostate cancer (CaP) remains among the most common causes of cancer related deaths in men. Because CaP is characterized by unique prostate associated antigens, it has been considered among prime candidates for immunotherapy. Despite numerous laboratory advances, clinical outcomes have been partial and transient. One plausible reason for the incomplete response is that vaccine cells, prepared under standard tissue culture conditions, can drastically differ in expression of macromolecules in situ, and thus may immunize against a less complete antigen spectrum. The purpose of the proposed studies is to optimize the effectiveness of therapeutic whole cell CaP vaccines by taking into consideration tumor associated hypoxia as a relevant determinant factor of tumor antigenicity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2013
- Accession Number
- ADA592082
Entities
People
- Christian R. Gomez
Organizations
- University of Mississippi Medical Center